Breast cancer spread into a separate kidney cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2 equivocal

Metastatic Site: bone|kidney

The kidney surgery unexpectedly confirmed a new breast-cancer metastasis, changing her breast cancer status to systemic progression. A new systemic treatment was planned.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient StoryRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Stage II Breast Cancer: Wendi's Survivor Story

Patient Info: Wendi Kushner | Stage II

Biomarkers: Triple-positive

After the clinical trial, lumpectomy pathology showed a complete pathological response with no residual cancer in the breast or lymph nodes.

MD AndersonRead more →

Hidden metastatic breast cancer found in bone marrow during blood-cancer monitoring

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive

Metastatic Site: bone marrow, bone

More than 7 years after metastatic breast carcinoma was first identified in 2018, she had stable skeletal disease and ongoing biochemical improvement on palbociclib plus fulvestrant in March 2026.

PubMed CentralRead more →

Stable Stage IV breast cancer after a serious side effect from abemaciclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: bone marrow

About 2 years after starting treatment, she remained on reduced-dose abemaciclib without disease progression.

PubMed CentralRead more →

Stage IV Breast Cancer: Betty's Patient Story

Patient Info: Betty Jean, Female | Stage IV

Metastatic Site: Spine; ribs; liver

As of June 2026, Betty Jean was living with Stage IV metastatic breast cancer after bone involvement in the spine/ribs and later progression to the liver, with treatment including targeted therapy, radiation, and chemotherapy.

The Patient StoryRead more →

Stage IV Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage IV

Metastatic Site: Bones; liver; lymph nodes; stomach

As of June 2026, Bethany was living with Stage IV metastatic breast cancer and responding well to maintenance treatment, with scans described as phenomenal and disease areas shrinking or disappearing.

The Patient StoryRead more →

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient StoryRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Breast cancer treatment during pregnancy followed by postpartum targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

She achieved a near-complete response after 4 cycles of docetaxel and then continued systemic treatment after delivery.

PubMed CentralRead more →

Stage IV BRCA Breast Cancer: Maralee's Survivor Story

Patient Info: Maralee, Female, Under 40 | Stage IV

Biomarkers: BRCA mutation

Metastatic Site: Brain

As of May 2026, Maralee had no evidence of active disease after prior Stage IV breast cancer with brain metastasis, had stopped the PARP inhibitor after 2 years, remained without brain recurrence long enough to pursue pregnancy, and gave birth to a second daughter.

Cleveland ClinicRead more →

Stage IV Breast Cancer: Erica's Patient Story

Patient Info: Erica, Female, 40s | Stage IV

Biomarkers: Hormone-positive; HER2-negative

Metastatic Site: Bone — ribs, sternum, spine, femur/right hip, shoulder…

Living with stable Stage IV hormone-positive, HER2-negative metastatic breast cancer involving multiple bones, currently managed with monthly hormone-suppressant injections and monitoring.

The Patient StoryRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Christina's Patient Story

Patient Info: Christina, Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Liver; lymph nodes

Christina was living with Stage IV HER2-positive metastatic breast cancer. Treatment had cleared the liver disease and removed the visible breast tumor, but small armpit lymph-node disease required radiation and she continued IV treatment every 3 weeks.

The Patient StoryRead more →

Triple-Negative Breast Cancer: Jacqueline's Patient Story

Patient Info: Jacqueline Bennett, Female, Under 40

Biomarkers: Initial ER-negative, PR-negative, HER2-negative; later HER2-positive

Jacqueline completed treatment for initial Stage IA triple-negative breast cancer during pregnancy and later developed a HER2-positive, hormone receptor-negative breast cancer. After 3 of 6 current treatments, the tumor was no longer visible on ultrasound or MRI, with targeted therapy and double mastectomy still planned.

The Patient StoryRead more →

Stage IV ER-positive/HER2-negative breast cancer with synchronous gastric and bone metastases

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Gastric metastasis showed ER-positive, PR-negative, HER2 0 lobular breast cancer. Breast primary was ER/PR-positive, HER2-negative

Metastatic Site: bone; stomach/gastric

At 2-month follow-up, upper-GI symptoms had improved, anastrozole plus palbociclib was tolerated, and CT showed stable disease with persistent diffuse osseous metastases; no further follow-up was available.

PubMed CentralRead more →

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed CentralRead more →